| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC20736 | AZD 9272 | A potent, selective, highly CNS-penetrant and orally available mGluR5 negative allosteric modulator Kd of 2.8 nM. |
|
| DC20723 | AZD 2066 | A potent, selective, highly CNS-penetrant mGluR5 antagonist. |
|
| DC22679 | CM 572 | A potent, selective, irreversible sigma-2 receptor partial agonist with Ki of 14.6 nM, >700-fold selectivity over sigma-1 receptors. |
|
| DC23412 | BMS-955829 | A potent, selective, low glutamate fold shift (2.4) mGluR5 positive allosteric modulator with EC50 of 2.6 nM, without inherent mGluR5 agonist activity (EC50>30 uM). |
|
| DC22804 | CMPD-1 | A potent, selective, non-ATP-competitive inhibitor of p38α-mediated MK2a phosphorylation with apparent Ki of 330 nM. |
|
| DC22742 | KAB-18 | A potent, selective, noncompetitive human α4β2 nAChRs negative allosteric modulator with IC50 of 13.5 uM, displays no inhibitory activity on Hα3β4 nAChRs at 100 uM.. |
|
| DC23195 | CBR-5884 Featured | A potent, selective, noncompetitive inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH) with IC50 of 7 uM. |
|
| DC22449 | PD-146176 | A potent, selective, non-competitve inhibitor of 15-lipoxygenase (15-LOX) with Ki of 197 nM. |
|
| DC22447 | FAAH-IN-2 | A potent, selective, noncovalent FAAH inhibitor with IC50 of 28 nM toward human FAAH and 100 nM toward rat FAAH. |
|
| DC22680 | Conivaptan | A potent, selective, nonpeptide vasopressin V1A and V2 receptor antagonist with Ki of 0.48 nM and 3.04 nM respectively. |
|
| DC21738 | TBC3486 | A potent, selective, non-peptidic integrin α4β1 (VLA-4) antagonist with IC50 of 9 nM, displays 200-fold selectivity over α4β7 (IC50=2.1 uM). |
|
| DC20617 | AA-CW236 Featured | A potent, selective, non-pseudosubstrate inhibitor of O(6) -alkylguanine DNA methyltransferase (MGMT) with low-nanomolar potency. |
|
| DC21593 | RUC-4 Featured | A potent, selective, non-RGD-mimetic αIIbβ3 integrin receptor antagonist with IC50 of 45 nM, with no activity on αVβ3 receptors. . |
|
| DC23596 | Luseogliflozin | A potent, selective, orally acitve SGLT2 inhibitor with IC50 of 2.26 nM, 1650-fold selectivity over SGLT1. |
|
| DC21307 | MKC-733 | A potent, selective, orally active 5-HT3 receptor agonist with high affinity for canine intestinal smooth muscle 5-HT3 receptors. |
|
| DC21606 | SB-357134 | A potent, selective, orally active and CNS penetrant 5-HT6 receptor antagonist with pKi of 8.5, displays 1300-fold selectivity over other 13 5-HT receptor subtypes. |
|
| DC20774 | VTP 37948 | A potent, selective, orally active BACE1 inhibitor for the treatment of Alzheimer's disease.. |
|
| DC20665 | AMG 8718 | A potent, selective, orally active BACE1 inhibitor with IC50 of 0.7 nM, demonstrates limited selectivity for over BACE2 and high selectivity both renin and pepsin. |
|
| DC20324 | BRS-3 agonist Compound A | A potent, selective, orally active bombesin receptor subtype-3 (BRS-3) agonist with EC50 of 250/100 nM for human/rat BRS-3, resp+H1437+M1438. |
|
| DC20325 | BRS-3 agonist Compound A racemate | A potent, selective, orally active bombesin receptor subtype-3 (BRS-3) agonist with EC50 of 270/130 nM for human/rat BRS-3, respectively. |
|
| DC21187 | JTE907 Featured | A potent, selective, orally active cannabinoid CB2 receptor inverse agonist with Ki of 35.9, 1.55 and 0.38 nM for human, mouse and rat CB2, respectively. |
|
| DC21793 | VER-250840 | A potent, selective, orally active Chk1 inhibitor with IC50 of < 1 nM, Ki=69 pM. |
|
| DC22898 | L-365260 | A potent, selective, orally active cholecystokinin receptor 2 (CCK2) antagonist with IC50 of 2 nM. |
|
| DC22485 | Gefitinib hydrochloride Featured | A potent, selective, orally active EGFR inhibitor with IC50 of 23 nM. |
|
| DC21443 | ONO-5334 | A potent, selective, orally active inhibitor of cathepsin K with Ki of 0.1 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. |
|
| DC23340 | CCT-251455 | A potent, selective, orally active monopolar spindle 1 (MPS1) inhibitor with IC50 of 3 nM, with no activity for CDK2 and Aurora A (IC50>40 uM). |
|
| DC25200 | PF-1355 Featured | PF-1355 is a potent, selective, orally active Myeloperoxidase (MPO) inhibitor with EC50 of 1.47 uM. |
|
| DC22900 | MLE-4901 Featured | A potent, selective, orally active neurokinin 3 (NK3R) antagonist for the treatment of schizophrenia. |
|
| DC22664 | Fezolinetant Featured | Fezolinetant is an antagonist of the neurokinin 3 receptor (NK3R), used for the treatment of menopausal hot flushes. |
|
| DC22686 | SCH 221510 | A potent, selective, orally active nociceptin opioid receptor (NOP) agonist with EC50 of 12 nM, Ki of 0.3 nM. |
|
